Tests two immune-lowering treatments for IgA nephropathy with advanced kidney disease
Compares low-dose prednisolone alone with prednisolone plus cyclophosphamide in adults with IgA nephropathy.
Plain-language title generated from the registry record
Registry title: Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD
Key facts
- Where
- Xi'an, ChinaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with IgA nephropathy confirmed by kidney biopsy, with protein in the urine and reduced kidney function despite maximum tolerated RAS blocker treatment.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- IgA nephropathy confirmed by biopsy, with proteinuria of 1.0 g/day or more and an estimated glomerular filtration rate of 15-60 ml/min/1.73/m2 (stage 3 or 4 chronic kidney disease)
- Earlier treatment
- Must be taking the maximum tolerated dose of RAS blockade. Must not have used corticosteroids or other immunosuppressive drugs in the last 1 year.
- Biomarker or test result
- Proteinuria of 1.0 g/day or more; estimated glomerular filtration rate 15-60 ml/min/1.73/m2
Main reasons for not taking part
- Use of corticosteroids or other immunosuppressive drugs within the last 1 year
- Unstable kidney function for other reasons
- Secondary IgA nephropathy
- Under 18 years old
- Unlikely to follow the study plan, in the treating doctor's view
Read by machine on 9 November 2026.
Where in China
- AFMMUXi'an, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Air Force Military Medical University, China
- Trial code
- NCT05510323
- Record updated
- 6 May 2024
- Original description
The purpose of this clinical trial is to evaluate the long-term efficacy and safety of low-dose oral corticosteroids combined with cyclophosphamide therapy and low-dose corticosteroids monotherapy, on a background of maximal RAS inhibitor therapy, for IgA nephropathy with stage 3 or 4 chronic kidney disease.Read full original descriptionShow less
Efficacy and Safety of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 Chronic Kidney Disease
The purpose of this clinical trial is to evaluate the long-term efficacy and safety of low-dose oral corticosteroids combined with cyclophosphamide therapy and low-dose corticosteroids monotherapy, on a background of maximal RAS inhibitor therapy, for IgA nephropathy with stage 3 or 4 chronic kidney disease.
Inclusion: Biopsy-proven IgA nephropathy; Proteinuria ≥1.0g/day while receiving maximum tolerated dose of RAS blockade; Estimated glomerular filtration rate 15-60 ml/min/1.73/m2.
Exclusion: Indication or contraindication for immunosuppressive therapy with corticosteroids; Use of corticosteroids and other immunosuppressive drugs within the last 1 year; Under 18 years old; Current unstable kidney function for other reasons; Patients with secondary IgAN; Patients who are unlikely to comply with the study protocol in the view of the treating physician.